雷替曲塞对人胃癌细胞MGC-803裸鼠移植瘤的抑制作用

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1166 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the inhibitive effect of raltitrexed on MGC-803 human gastric cancer xenografts in nude mice, and to explore the mechanisms tentatively.Methods Models of human gastric cancer in nude mice were established by subcutaneous transplantation before 24 mice were randomly assigned into three groups: control group (normal saline),low-dose group (raltitrexed, 5 mg/kg) and high-dose group (raltitrexed, 12 mg/kg). Drugs were injected into the abdominal cavity twice a week for two weeks. The tumor size, mouse weight and mental state were recorded. Immunohistochemistry was used to detect the expression levels of Ki67 and PCNA, while the expression of Caspase-3 and Bax was analyzed using Western blotting.Results The duration of raltitrexed treatment was shorter and the body weight of the nude mice was lower than those of the control group. The tumor inhibition rate of the low-dose group and high-dose group was 27.54% and 44.20% respectively, so there was significant difference between the two groups. IHC Results showed that the Ki67 positive rate of cells was 58.95% and 42.16% respectively in the low-dose group and high-dose group, while the PCNA positive rate of cells was 51.36% and 37.27% respectively. Significant difference of Ki67 and PCNA expressions was found between these groups(P<0.05). Western blotting showed increased expressions of Caspase-3 and Bax in the two treatment groups(P<0.05), especially in the high-dose group (P<0.05).Conclusions Raltitrexed can inhibit human gastric cancer xenografts in nude mice.The mechanism may be related to enhanced expressions of Caspase-3 and Bax that promoted apoptosis.

Key words： raltitrexed gastric cancer Ki67 PCNA Caspase-3 Bax

Received: 11 December 2018

ZTFLH:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2019/V30/I7/611

[1]	陈万青, 孙可欣, 郑荣寿,等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(1):1-14.
[2]	陈冠华, 黄鹏, 白玉贤. 雷替曲塞治疗结直肠癌的研究进展[J]. 现代肿瘤医学, 2016, 24(19):3169-3172.
[3]	Xue S, Chen Y X, Qin S K, et al. Raltitrexed induces mitochondrialmediated apoptosis in sgc7901 human gastric cancer cells [J]. Mol Med Rep, 2014,10(4):1927-1934.
[4]	陈钟, 唐庆林, 韩忠政,等. 胃癌的治疗进展[J]. 国际消化病杂志, 2017, 37(2):77-78.
[5]	De M P R, Lima de D A, Pauli K B, et al. Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.[J]. Parasitol Res, 2018, 117(14):1-7.
[6]	吴振海,曲秀娟.雷替曲塞在晚期结直肠癌中的应用进展[J].中华结直肠疾病电子杂志,2018,7(1):62-66.
[7]	薛松, 陈映霞. 雷替曲塞治疗胃癌的研究进展[J]. 国际肿瘤学杂志, 2016, 43(7):535-537.
[8]	师鲁静, 高海德, 柳仲林,等. 雷替曲塞对人胃癌细胞Livin基因表达的影响[J]. 中华实验外科杂志, 2014, 31(8).
[9]	徐瀚峰, 朱传东, 王礼学,等. 奥曲肽联合雷替曲塞对胃癌细胞株SGC-7901增殖的影响[J]. 现代中西医结合杂志, 2013, 22(30):3317-3319.
[10]	洪雷, 李华, 常靓,等. 雷替曲塞对人胃癌裸鼠移植瘤生长的影响及其机制[J]. 中国肿瘤临床, 2014(12):766-770.
[11]	马世华, 施能胜, 卞元清. 注射用雷替曲塞对胃癌患者癌细胞的影响及作用机制研究[J]. 河北医学, 2017,23(10):1667-1670.
[12]	Tan P P, Zhou B H, Zhao W P, et al. Mitochondria-mediated pathway regulates C2C12 cell apoptosis induced by fluoride[J]. Biol Trace Elem Res, 2018(1):1-8.
[13]	向军军, 赖菁菁, 胡跃强. 近3年线粒体介导细胞凋亡的研究进展[J]. 中西医结合心脑血管病杂志, 2016, 14(13):1497-1499.
[14]	姚洁, 薛玲珑. 凋亡相关因子p21和Caspase-3及Survivin在胃癌中的研究进展[J]. 临床医药实践, 2016, 25(10):774-777.
[15]	Rogers C, Fernand T, Mayes L, et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death[J]. Nat Commun, 2017, 8:14128.
[16]	孙云, 胡晓杰, 马国娟,等. 胃癌组织中LMO1与Bcl-2、Bax、Survivin、Caspase-3蛋白表达的关系及意义[J]. 肿瘤学杂志, 2016, 22(9):703-707.
[17]	Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.[J].Nat Rev Drug Discov, 2017, 16(4):273-284.
[18]	朱玉侠, 赵明星, 姜登鸽,等. 抑癌基因p53、凋亡抑制基因Bcl-2、促凋亡基因Bax在胃癌及癌前病变中的表达[J]. 胃肠病学和肝病学杂志, 2016, 25(9):1040 -1043.